Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52-week follow-up/End of study visit, Subjects will be followed for an additional 104 week period, with an assessment occurring every 12 weeks to evaluate survival outcomes and next line of treatments only.

Study Overview

• Status: Recruiting
• Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome
• Intervention / Treatment: Drug: Etoposide; Drug: Cyclophosphamide; Drug: Prednisone; Drug: Polatuzumab Vedotin; Drug: Rituximab; Drug: Hydroxydaunomycin

Detailed Description

This is an open label, single arm, phase II investigator initiated clinical trial, evaluating efficacy and safety of Polatuzumab vedotin added to a modified infusional dose adjusted R-EPOCH like regimen, given on an inpatient basis, every 21 days, in subjects with Richter's Transformation.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Amelyn Rodriguez, R.N.; Phone Number: 2127461362; Email: amr2017@med.cornell.edu
• Study Contact Backup: Name: Katherine Greig, R.N.; Phone Number: 2127466738; Email: kag9156@med.cornell.edu

Study Locations

• United States
  • New York
    • New York, New York, United States, 10065
      • Recruiting
      • Weill Cornell Medicine
      • Principal Investigator: John Allan, M.D.
      • Contact: Katherine Greig, R.N.; Phone Number: 2127466738; Email: kag9156@med.cornell.edu
      • Contact: Amelyn Rodriguez, R.N.; Phone Number: 212-746-1362; Email: amr2017@med.cornell.edu
    • New York, New York, United States, 10032
      • Recruiting
      • Columbia University Medical Center
      • Contact: Andrew Lipsky, MD
      • Principal Investigator: Andrew Lipsky, MD
    • New York, New York, United States, 10029
      • Recruiting
      • Mount Sinai- Icahn School of Medicine
      • Principal Investigator: Suchitra Sundaram, MD
      • Contact: Suchitra Sundaram, MD
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Recruiting
      • Ohio State University
      • Contact: Adam Kittai
      • Principal Investigator: Adam Kittai, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject must have confirmed diagnosis of CLL based upon 2018 International Workshop on CLL (IwCLL) criteria, with biopsy proven Richter's Transformation to a DLBCL subtype.
• Subject must be ≥18 years of age.
• Subject must be able to sign informed consent
• Ability and willingness to comply with the study protocol procedures
• Life expectancy of at least 24 weeks
• Subject must have an Eastern Cooperative Oncology Group performance status of ≤2.
• Subject must have measurable disease with atleast on LN>- 1.5cm in longest diameter

• Subject must have adequate bone marrow function and meet the below thresholds prior to treatment.

  • Absolute neutrophil count of ≥1000 cell/uL
  • Hemoglobin ≥ 7 g/dL
  • Platelet count ≥ 30,000 cells/uL

• Subject must have adequate organ function and meet the thresholds below:

  • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's disease will be granted exception to this rule.
  • Creatinine clearance >30 ml/min/1.73m2 as calculated by the MDRD equation.
  • Ejection fraction ≥ 50% measured by transthoracic echocardiogram or MUGA scan

• For women of childbearing potential: agreement to remain abstinent or use of contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 12 months after the last dose of study drug.

  • A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (i.e. ≥ 12 months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and or uterus)

    • Acceptable forms of contraception are bilateral tubal ligation, male sterilization, or copper intrauterine devices.
  • For women considered to have childbearing potential a negative serum pregnancy test within 7 days prior to study enrollment and dosing is required.

• For men, agreement to remain abstinent, or to use a condom plus an additional contraceptive method during the treatment period and for at least 5 months after the last dose of study drug.

  • Men must agree not to donate sperm during that period of time. Male patients interested in preservation of fertility should be advised to sperm bank prior to enrollment and treatment initiation.

Exclusion Criteria:

• Diagnosis of Richter's Transformation not of DLBCL subtype (including but not limited to Hodgkin lymphoma, PLL)
• Prior therapy targeting Richter's transformation.
• Any subject that initiates a targeted agent such as BTKi, venetoclax, or PI3K prior to enrollment (Continuation of a targeted CLL directed therapy such as a BTKi, venetoclax, or PI3K will be permitted as a bridge through screening but add on therapies or change in therapy will be exclusionary. These continuation therapies will be permitted up 72 hours prior to study initiation. Bridging therapy with steroid up to equivalent of 40mg of Dexamethasone daily will be allowed prior to study treatment and can be continued up to 24 hours prior to study treatment)
• Subject has undergone an allogeneic stem cell transplant for CLL within 6 months of study entry.
• Subject has an active or presumed secondary malignancy at time of enrollment. A subject will be eligible if a previous malignancy was treated with curative intent and there is no evidence of disease recurrence for the past 3 years. Non-melanomatous and cervical squamous cell cancers are an exception and if excised will be allowed to enroll regardless of timing of excision.
• Subject is known to be positive for HIV.
• Active hepatitis C or hepatitis B defined by positive PCRs for viral DNA/RNA. Subjects with a positive Hep B core antibody and negative PCR, are allowed to enroll (prophylaxis is strongly encouraged and monthly monitoring of Hep B PCR is mandatory).
• Subject has baseline ≥ Grade 2 or greater peripheral neuropathy.
• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• Clinical evidence or known central nervous system involvement with transformed large cells
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
• Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina)
• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 4 weeks before Cycle 1 day 1.
• Major surgery within 4 weeks before the start of Cycle 1 day 1. Superficial lymph node biopsies or laprascopic lymph node biopsies are exclusionary to this rule.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Polatuzumab vedotin plus R-EPCH; Polatuzumab vedotin will be given in conjunction with 6 cycles of R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, hydroxydaunorubicin). The dosing schedule and regimen for R-EPCH will follow established protocols. Polatuzumab vedotin will be administered on Day 1 of each 21-day cycle.

Drug: Etoposide; Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.; Other Names: VP-16; VePesid; etopophos; toposar; Drug: Cyclophosphamide; Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.; Other Names: cytoxan; Drug: Prednisone; Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.; Other Names: Deltasone; Orasone; Paracort; Cortan; Drug: Polatuzumab Vedotin; Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.; Other Names: Polivy; Drug: Rituximab; Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.; Other Names: Rituxan; chimeric anti-CD20 monoclonal antibody; Drug: Hydroxydaunomycin; Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.; Other Names: Hydroxydoxorubicin Hydrochloride; Doxorubicin Hydrochloride

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete metabolic remission/complete remission (CMR/CR) rate of subjects at end of treatment (EOT)	Percentage of subjects who achieve CMR/CR on study.	19 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of polatuzumab vedotin plus infusional chemoimmunotherapy (CIT) containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin in patients with newly diagnosed Richter's Transformation.	Percentage of subjects who experience 1 or more adverse events.	1.5 years
Overall response rate (ORR)	Rate of subjects who achieve a partial or complete response.	3 years
Progression free survival (PFS)	Measured from time of first study drug administration to objective or symptomatic progression or death.	3 years
Overall survival (OS)	Measured from time of first study drug administration to death from any cause.	3 years
Allogeneic transplantation rate in eligible patients	Percentage of eligible patients able to get allogeneic stem cell transplant.	3 years

Collaborators and Investigators

• Sponsor: Weill Medical College of Cornell University
• Collaborators: Genentech, Inc.
• Investigators: Principal Investigator: John Allan, M.D., Weill Medical College of Cornell University

Publications and helpful links

Helpful Links

• WCM Joint Clinical Trials Office

Study record dates

Study Major Dates

• Study Start (Actual): September 24, 2021
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): September 1, 2026

Study Registration Dates

• First Submitted: December 16, 2020
• First Submitted That Met QC Criteria: December 16, 2020
• First Posted (Actual): December 22, 2020

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: CLL; Richter's Transformation; Polatuzumab vedotin
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease Attributes; Leukemia, Lymphoid; Leukemia; Leukemia, B-Cell; Chronic Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Immunoconjugates; Cyclophosphamide; Etoposide; Rituximab; Prednisone; Doxorubicin; Liposomal doxorubicin; Polatuzumab vedotin
• Other Study ID Numbers: 20-08022533

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No